No Data
This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?
According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.
Many innovative drugs stocks in Hong Kong suddenly soared!
On the morning of November 25, the hang seng index fell slightly, while the Hong Kong stock market's biomedical sector performed well. Notably, several biomedical companies saw their stock prices rise significantly due to recent news of major collaboration advancements.
The world's first active sperm detection device is on the market! BeiKang Medical-B (2170.HK) Smart Sperm Analyzer is expected to replace the traditional CASA diagnostic mode!
On November 4, 2024, in Suzhou, china /PRNewswire/ -- According to the latest data from the National Health Commission's Department of Maternal and Child Health, there are currently 602 medical institutions nationwide that have been approved to carry out human assisted reproduction technology, with the number of IVF institutions globally continuing to increase. These institutions, in terms of sperm testing technology, mainly use the Computer-Assisted Sperm Analysis (CASA) method to analyze sperm quantity, vitality, morphology, etc. based on the standards of the fifth edition of WHO guidelines. From the demand side, the decline in sperm quality among Chinese males has become a confirmed fact. A Frost & Sullivan report pointed out that Chinese males have recently
Suzhou Basecare Medical Gets Registration Go-Ahead for Sperm Quality Analyzer From Jiangsu Regulator
Beacon Medical-B (2170.HK) sperm quality analyzer obtained the medical instruments registration certificate issued by Jiangsu Drug Administration.
Gelonghui Nov. 1st | Beckon Medical-B (2170.HK) announced that the sperm quality analyzer (BKA210) developed by the company obtained the medical device registration certificate issued by the Jiangsu Provincial Pharmaceutical and Medical Instruments Administration on November 1, 2024 (Registration number: SUXIE ZHUN 20242222101). BKA210 is the world's first device developed independently based on the "WHO Laboratory Manual for the Examination and Processing of Human Semen (Sixth Edition)" that can detect unstained living sperm. The instrument won the Outstanding Project Award at the national groundbreaking technology innovation competition in 2021, and has the following advantages: 1.
Beacon Medical (02170.HK) sperm quality analyzer obtained the medical instruments registration certificate issued by the Jiangsu Pharmaceutical Supervision Bureau.
Beikang Medical (02170.HK) announced that the Sperm Quality Analyzer (BKA210) obtained the medical instrument registration certificate issued by the Jiangsu Pharmaceutical Supervision Bureau today (1st) (Registration No.: SuXieZhuN20242222101).
No Data
No Data